The robust efficacy across PD-L1 subgroups and manageable safety profile de-risk pumitamig's Phase 3 program. Monitor upcoming data from Phase 3 trials (ROSETTA Lung-02, Lung-201, Lung-202) and potential regulatory filings. The partnership with BMS provides strong commercial infrastructure. Near-term catalyst: further Phase 3 readouts in NSCLC and other indications.
Price Chart
Executive Summary
BioNTech and BMS announced positive interim Phase 2 data for pumitamig (PD-L1xVEGF bispecific) plus chemotherapy in first-line NSCLC at ASCO 2026. The data showed high confirmed objective response rates (cORR) of 63.6% in non-squamous and 72.7% in squamous NSCLC at the lower dose, with 100% disease control rate and manageable safety. This supports the ongoing Phase 3 program and positions pumitamig as a potential new standard of care across PD-L1 expression levels.
Key Facts
- Interim Phase 2 data from ROSETTA Lung-02 trial (NCT06712316) presented at ASCO 2026
- cORR of 63.6% in non-squamous and 72.7% in squamous NSCLC at the lower 1400 mg dose
- 100% disease control rate (DCR) across all evaluable patients
- cORR by PD-L1 expression: 47.6% (TPS <1%), 77.8% (TPS 1-49%), 100% (TPS ≥50%)
- Grade ≥3 treatment-related adverse events in 48.8% of patients; pumitamig-related in 23.3%
- Treatment discontinuation due to AEs in 4 patients (9.3%)
- Phase 3 part of ROSETTA Lung-02 actively enrolling; two additional global Phase 3 trials in NSCLC ongoing
- Seven global Phase 3 trials with registrational potential currently ongoing across multiple indications
Financial Impact
No financial figures provided; clinical data supports potential multi-billion-dollar peak sales opportunity if approved in first-line NSCLC, a large market (~85% of lung cancer cases)
Risk Factors
- Phase 3 trials may fail to replicate Phase 2 efficacy or show unexpected safety signals
- Competition from existing PD-(L)1 inhibitors and other bispecifics in development
- Regulatory approval not guaranteed; manufacturing and commercial execution risks
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3303897 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 14, 2026 18d ago | 6-K | $98.86 $98.00 | ▼ −0.87% | ▼ −0.98% | $96.97 (−1.91%) |
Sep 14, 2026 18d ago | Press Release | $98.86 $98.00 | ▼ −0.87% | ▼ −0.98% | $96.97 (−1.91%) |
Aug 28, 2026 5w ago | 6-K | $102.08 $103.76 | ▼ −1.65% | ▼ −1.54% | $96.97 (+5.00%) |
Aug 20, 2026 6w ago | 6-K | $110.89 $111.40 | ▲ +0.46% | ▼ −0.65% | $96.97 (−12.55%) |
Aug 11, 2026 7w ago | Institutional Cluster | $92.80 $92.75 | ▼ −0.05% | ▲ +0.35% | $96.97 (+4.50%) |
Aug 4, 2026 8w ago | 6-K | $91.35 $92.80 | ▼ −1.59% | ▼ −1.69% | $96.97 (−6.16%) |
Aug 3, 2026 8w ago | 6-K | $92.25 $92.80 | ▲ +0.60% | ▼ −1.43% | $96.97 (+5.12%) |
Aug 3, 2026 8w ago | Press Release | $92.25 $92.80 | ▲ +0.60% | ▼ −1.43% | $96.97 (+5.12%) |
Jul 29, 2026 9w ago | 6-K | $92.85 $91.19 | ▼ −1.79% | ▼ −5.41% | $96.97 (+4.44%) |
Jun 8, 2026 16w ago | 6-K | $85.50 $90.80 | ▲ +6.20% | ▲ +4.09% | $96.97 (+13.42%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access